Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-12
2005-04-12
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S272000, C544S295000, C544S296000, C544S315000, C544S316000, C544S322000, C544S323000, C544S324000
Reexamination Certificate
active
06878717
ABSTRACT:
This invention concerns the use of compounds of formula:the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein -a1=-a2-a3=a4- forms a phenyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5; R1is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxy-carbonyl, substituted C1-6alkyl, or substituted C1-6alkyloxyC1-6alkylcarbonyl; each R2independently is hydroxy, halo, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C3-7cycloalkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalo-methylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6or a 5-membered heterocyclic ring; p is 1 or 2; L is optionally substituted C1-10alkyl, C2-10alkenyl, C2-10alkynyl or C3-7cycloalkyl; or L is —X—R3wherein R3is optionally substituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; X is —NR1—, —NH—NH—, —N═N—, —O—, —C(═O)—, —CHOH—, —S—, —S(═O)— or —S(═O)2—; Q is hydrogen, C1-6alkyl, halo, polyhalo-C1-6alkyl or an optionally substituted amino group; Y represents hydroxy, halo, C3-7cycloalkyl, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6or aryl; aryl is optionally substituted phenyl; Het is an optionally substituted heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.
REFERENCES:
patent: 4659363 (1987-04-01), Hubele et al.
patent: 5691364 (1997-11-01), Buckman et al.
patent: 6048866 (2000-04-01), Hutchings et al.
patent: 6093716 (2000-07-01), Davis et al.
patent: 6197779 (2001-03-01), Andries et al.
patent: 0135472 (1985-03-01), None
patent: 0135472 (1985-03-01), None
patent: 0588762 (1994-03-01), None
patent: 0 371 139 (1994-10-01), None
patent: 834507 (1998-04-01), None
patent: 0945443 (1999-09-01), None
patent: 9454442 (1999-09-01), None
patent: WO 9510506 (1995-10-01), None
patent: WO 9841512 (1998-09-01), None
Vingerhoets,Antiviral activity TMC 125 SDM, CROI, San Francisco, Feb. 2004.
Arnold,Conformational Flexibility of DAPYs: activity against resistant HIV, Aug. 2003.
Vingerhoets.Resistance before/after therapy—TMC 125C207, XII Resistance Mexico, Jun. 2003.
Vingerhoets,Resistance profile clinical isolates TMC 125, XII Resistance Mexico, Jun. 2003.
Gazzard,TMC 125 C207 study treatment-experienced, CROI Seattle, Feb. 2002.
Lange,TMC 125 decay rate vs ERA, CROI Seattle, Feb., 2002.
Gazzard,7 day treatment-experienced, WAC Barcelona, Jul. 2002.
Lewi,Potancy&multiple binding modes of TMC 125, CROI Boston, Feb. 2003.
M-P de Bethune,TMC 125 resistance profiles, Resistance, Mexico, Jun. 2003.
Vingerhoets,TMC 125-C207 resistance analysis, Resistance, Mexico, Jun. 2003.
TMC 125 for 7 days in HIV-1+ Individuals with NNRTI resistance(TMC 125-C207), AIDS, 17(18): F49-54, Dec. 5, 2003.
TMC 125 as 7d monotherapy in ARV-naive subjects(TMC 125-C208), AIDS, 17(17): 2487-2494, Nov. 21, 2003.
TMC 125 similar potancy to 5-drug, 3-class regimen, AIDS, 17(18): 2623-2627Dec. 6, 2003.
Udier-Blagovic,Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125, Journal of American Chemical Society, 2003, 125(20), pp. 6016-6017.
Gulick,New Antiretroviral drugs, Clinical Microbiology and Infection, 2003, 9(3), pp. 186-193.
Ludovici,Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine, (DAPY)analogues.Bioorganic & Medicinal Chemistry Letters (2001), 11(17), pp. 2235-2239.
Gruzdev, et al.,A Randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive HIV-1 infected subjects, AIDS 2003, vol. 17, pp. 2487-2494.
Sankatsing, et al.,TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen, AIDS 2003, vol. 17, pp. 2623-2627.
Gazzard, et al.,An open-label assessment of TMC 125—a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance, AIDS 2003, vol. 17, pp. 49-54.
Ludovici, et al.,Evolution of Anti-HIV Drug Candidates. Part 3: Diarylpyrimidine(DAPY)Analogues, Bioorganic & Medical Chemistry Letters 11, 2001, pp. 2235-2239
Udier-Blagović, et al.,Validation of a Model for the Complex of HIV-1 Reverse Transcriptase with Nonnuceloside Inhibitor TMC125, J. Am. Chem. Soc. 2003, vol. 125, pp. 6016-6017.
Gulick, New Antiretroviral Drugs, Clinical Microbiology and Infectious Diseases, CMI, 9, (3) pp. 186-193 (Mar., 2003).
Furukawa, et al., Syntheses of Compounds related to Guanidine and their Inhibitory Action on Growth of HeLa Cells, Chem. Pharm. Bull. 9(11), 914-921 (1951).
Gazzard, et al., TMC125, A Next-Generation NNRTI, Demonstrates High Potency After 7 Days Therapy in Treatment-Experienced HIV-1 Infected Individuals with Phenotypic NNRTI, CROI, Seattle, Feb. 2002.
Vingerhoets, et al., Antiviral activity of TMC125, a potent next-generation NNRTI, against >5000 recombinant clinical isolates exhibiting a wide range of (NNRTI) resistance, XIIth International HIV Drug Resistance Workshop, Jun. 10-14, 2003, Mexico.
Vingerhoets, et al., Characterization of Resistance Before and After Short-Term Therapy with TMC125 in Patients with Documented NNRTI Resistance, XIIth International HIV Drug Resistance Workshop, Jun. 10-14, 2003, Mexico.
Gazzard, et al., TMC125, a Next Generation NNRTI, Demonstrates High Potency After 7 Days Therapy in Treatment-Experienced HIV-1 Infected Individuals with Phenotypic NNRTI-Resistance, XIV International AIDS Conference, Jul. 2002, Barcelona, Spain.
Sankatsing, et al., TMC 125 Monotherapy for One Week Results in a Similar Initial Rate of Decline of HIV-1 RNA as Therapy With a 5-Drug Regimen, CROI, Seattle, Feb., 2002.
Arnold, et al., Inhibitor conformational flexibility and positional variation are important for activity against drug-resistant virus: crystal structures of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase, 21stEuropean Crystallographic Meeting, Durban, South Africa, Aug. 24-29, 2003.
Das, et al., Could multiple modes of binding of a potent NNRTI TMC125-R165335 explain its potency against common drug-resistant mutants? CROI, Boston, Feb. 2003.
J. Vingerhoets et al., Antiviral Activity of TMC Against a Panel of Site-Directed Mutants Encompassing Mutations Observed In Vitro and In Vivo, Poster No. 621, Presented at the XIth Conference on Retrovirus and Opportunistic Infections, Feb. 8-11, 2004, San Francisco, CA, USA.
De Corte Bart
De Jonge Marc Rene
Heeres Jan
Ho Chih Yung
Janssen Paul Adriaan Jan
Balasubramanian Venkataraman
Raymond Richard L.
LandOfFree
HIV replication inhibiting pyrimidines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV replication inhibiting pyrimidines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV replication inhibiting pyrimidines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3388828